-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47

Benzinga·04/30/2025 12:41:17
Listen to the news
HC Wainwright & Co. analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and lowers the price target from $74 to $47.